EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY 4.0

Efficacy and Safety of Immune Checkpoint Inhibitor Combination Strategies in pMMR/MSS Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis

Lielong Yang, Yuzhou Zhu, Mingtian Wei, Xuyang Yang, Tinghan Yang, Ziqiang Wang

Cancers · 20.11.2026 · 18 (22) · 3718

DOI: 10.3390/cancers18223718 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancers, online erschienen am 20.11.2026. Verfasst von Lielong Yang und 5 weiteren Autor:innen. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Immune checkpoint inhibitors (ICIs) have transformed the treatment of dMMR/MSI metastatic colorectal cancer (mCRC), whereas their value in the far more common pMMR/MSS phenotype remains unresolved because of its immune-cold biology. This systematic review and network meta-analysis evaluated the efficacy and safety of ICI-based combination strategies in pMMR/MSS mCRC.

Methods

Six international and Chinese databases were searched for randomized trials and non-randomized studies. Thirteen studies with 2157 patients were included; the primary outcome was progression-free survival (PFS), and secondary outcomes were overall survival (OS), objective response rate (ORR) and treatment-related adverse events (TRAEs). Effects were synthesized with a frequentist random-effects network meta-analysis.

Results

In the connected network (11 studies, 12 comparisons, 4 treatment nodes), ICI plus targeted therapy ranked first for PFS (HR 0.671, 95% CI 0.533–0.844 versus chemotherapy plus targeted therapy; P-score 0.881) and the triplet ICI + chemotherapy + targeted therapy was also associated with longer PFS (HR 0.772, 95% CI 0.621–0.961; P-score 0.549); between-study heterogeneity was moderate (I2 = 21.2%, tau2 = 0.0125, Q = 11.42, df = 9, p = 0.248), and the two ICI-containing strategies did not differ from each other (HR 1.151, 95% CI 0.839–1.581). Within the shared chemotherapy plus bevacizumab backbone, the first-line estimate (HR 0.76, 95% CI 0.59–0.97, three studies) did not differ from the later-line estimate (0.70, 0.51–0.95, two studies; p = 0.68 for the subgroup difference). The estimate was insensitive to how the LEAP-017 comparator arm was assigned (HR 0.671 versus 0.647 under the two codings) but remained significant in all 11 leave-one-out iterations. Because the OS and ORR contrasts were clinically non-comparable, they are reported study by study rather than as pooled treatment effects: only dual ICI plus best supportive care improved OS, and ORR was higher with ICI-containing regimens in nine of the fourteen study-level comparisons, lower in four and identical in one. Grade III-V TRAEs were, by contrast, more frequent with ICI-containing regimens in six of the seven study-level comparisons, with odds ratios from 1.25 to 7.12, the single exception being COLUMBIA-1, which counted treatment-emergent rather than treatment-related events.

Conclusions

In pMMR/MSS mCRC, ICI-based combinations show a modest and imprecisely estimated PFS advantage, most evident for ICI plus targeted therapy, at the cost of increased severe toxicity. The direct evidence is narrow, the ranking is exploratory, and practice should not change until adequately powered, biomarker-stratified randomized trials are available.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Yang, L., Zhu, Y., Wei, M., Yang, X., Yang, T., & Wang, Z. (2026). Efficacy and Safety of Immune Checkpoint Inhibitor Combination Strategies in pMMR/MSS Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis. Cancers, 18(22), 3718. https://doi.org/10.3390/cancers18223718

Vancouver

Yang L, Zhu Y, Wei M, Yang X, Yang T, Wang Z. Efficacy and Safety of Immune Checkpoint Inhibitor Combination Strategies in pMMR/MSS Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis. Cancers. 2026;18(22):3718. doi:10.3390/cancers18223718

BibTeX
@article{Yang2026,
  author = {Yang, Lielong and Zhu, Yuzhou and Wei, Mingtian and Yang, Xuyang and Yang, Tinghan and Wang, Ziqiang},
  title = {Efficacy and Safety of Immune Checkpoint Inhibitor Combination Strategies in pMMR/MSS Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {22},
  pages = {3718},
  doi = {10.3390/cancers18223718}
}
Kostenlos starten →